Alemtuzumab Induction Is Associated With Higher Risk of Polyomavirrus Associated Nephropathy (PVAN) in Kidney Transplant Recipients
1Transplant, Mayo Clinic, Jacksonville, FL
2Pharmacy, Mayo Clinic, Jacksonville, FL.
Meeting: 2015 American Transplant Congress
Abstract number: 426
Keywords: Induction therapy, Kidney transplantation, Polyma virus
Session Information
Session Name: Concurrent Session: BK Virus Infection After Kidney Transplantation
Session Type: Concurrent Session
Date: Tuesday, May 5, 2015
Session Time: 4:00pm-5:30pm
Presentation Time: 4:00pm-4:12pm
Location: Room 115-C
Incidence of PVAN on protocol kidney biopsies with alemtuzumab induction is unknown.Methods:The 1-year risk of PVAN was retrospectively compared between 200 consecutive primary kidney recipients who received either rabbit anti-thymocyte globulin (rATG) (n=100) or almetuzumab (n=100). All patients received 5 days of corticosteroids, tacrolimus (target 8-10 ng/ml 1st month then 6-8 ng/ml) and mycophenolate mofetil (MMF) at 2 gr/d. Patients with PRA >20% were excluded. Plasma BK PCR and protocol biopsies were obtained at 1,4 and 12 months post-tx. PVAN was treated with immunosuppression (IS) reduction. Results: Patients' and transplant characteristics are presented in Table 1
rATG (n=100) | Alemtuzumab (n=100) | P | |
Age (yr) | 56±13 | 52.8 ± 13.6 | 0.1 |
% Male | 53 | 57 | 0.6 |
% Caucasian | 51 | 57 | 0.2 |
% Living donor | 41 | 31 | 0.1 |
% Pre-emptive tx | 24 | 24 | 1 |
% DCD | 10 | 18 | 0.1 |
% DGF | 8 | 16 | 0.08 |
% ≥3 HLA match | 34 | 27 | 0.5 |
Cold ischemia time (hr) | 10±8 | 11±7 | 0.1 |
Warm ischemia time (min) | 37±13 | 39±12 | 0.3 |
To cite this abstract in AMA style:
Wadei H, Saull H, Enderby C, Mai M, Prendergast M, Gonwa T. Alemtuzumab Induction Is Associated With Higher Risk of Polyomavirrus Associated Nephropathy (PVAN) in Kidney Transplant Recipients [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/alemtuzumab-induction-is-associated-with-higher-risk-of-polyomavirrus-associated-nephropathy-pvan-in-kidney-transplant-recipients/. Accessed December 4, 2024.« Back to 2015 American Transplant Congress